The role of methylation in chemotaxis. An explanation of outstanding anomalies

The role of methylation in chemotaxis is understood generally, but several anomalies exist which bring into question the timing of methylation relative to sensing. A double mutant bacterium, deficient in both methyltransferase and methylesterase (Tr-Es-) is capable of chemotaxis even though the respective single mutants (Tr- and Es-) are not. This Tr-Es- mutant will accumulate in capillaries containing aspartic acid but not in capillaries containing serine despite the fact that both the aspartate and serine receptors are part of the methylation-dependent pathway. To understand these anomalies, a combination of theoretical analyses and experimental studies was performed. A mathematical analysis of the gradients of aspartate and serine in the capillary assay shows that outside the capillary the gradients are shallow, but just inside the mouth of the capillary they are very steep. Also, when the number of bacteria accumulated in the capillary is at a maximum, the range of attractant concentrations in the steep gradient just inside the mouth of the capillary is optimal for response and partial adaptation by the Tr-Es- mutant. We postulate that random motion brings the Tr-Es- mutant into the capillary, where it is able to move up the steep gradient. The difference in timing of the responses to serine and aspartate explains why the Tr-Es- mutant accumulates in aspartate- but not in serine-containing capillaries. A simple diffusion-capture model incorporating these concepts can account for experimental values of the number of Tr-Es- bacteria accumulating in the capillary. These studies provide a rational explanation for all of the apparent anomalies and lead to the conclusion that methylation/demethylation plays a crucial role in sensing as well as setting the zero point of the receptor.     

Determination of serum oxalate using peroxyoxalate chemiluminescence of free oxalic acid

We describe a new sensitive and specific method for determination of oxalate in human serum. By using the chemiluminescence decay of monoperoxyoxalic acid very low concentrations of oxalate (200 nmol/L) can be determined. The mean serum oxalate level in apparently healthy controls was 14.5 ± 8.5 m?mol/L. Supplementation of ascorbic acid leads to an increase in serum oxalate level. While serum oxalate concentrations of calcium oxalate stone formers (x = 16.4 ± 9.8 m?mol/L) are not significantly different from the control group, an extreme increase of serum oxalate is evident in haemodialysis patients. The serum oxalate concentration decreased during dialysis treatment from 141.4 ± 32.1 m?mol/L to 36.4 ± 12.7 m?mol/L.     

Transcriptional Profiling of Whole Blood Identifies a Unique 5-Gene Signature for Myelofibrosis and Imminent Myelofibrosis Transformation

Identifying a distinct gene signature for myelofibrosis may yield novel information of the genes, which are responsible for progression of essential thrombocythemia and polycythemia vera towards myelofibrosis. We aimed at identifying a simple gene signature – composed of a few genes - which were selectively and highly deregulated in myelofibrosis patients. Gene expression microarray studies have been performed on whole blood from 69 patients with myeloproliferative neoplasms. Amongst the top-20 of the most upregulated genes in PMF compared to controls, we identified 5 genes (DEFA4, ELA2, OLFM4, CTSG, and AZU1), which were highly significantly deregulated in PMF only. None of these genes were significantly regulated in ET and PV patients. However, hierarchical cluster analysis showed that these genes were also highly expressed in a subset of patients with ET (n = 1) and PV (n = 4) transforming towards myelofibrosis and/or being featured by an aggressive phenotype. We have identified a simple 5-gene signature, which is uniquely and highly significantly deregulated in patients in transitional stages of ET and PV towards myelofibrosis and in patients with PMF only. Some of these genes are considered to be responsible for the derangement of bone marrow stroma in myelofibrosis. Accordingly, this gene-signature may reflect key processes in the pathogenesis and pathophysiology of myelofibrosis development.